21
Oct
2009
Lux Biosciences | Series B $50M
Posted in NJ Private: Lux Biosciences, Series A, X - Ophthalmology, X - Therapeutic
Lux Biosciences, based in Jersey City, NJ and focused upon the development of ophthalmic disease, has relied upon an in-licensing strategy from corporate partners and academia for molecules and technologies that have demonstrated proof-of-concept in related non-ophthalmic diseases but where common mechanisms of action and biological pathway overlap may be levered.
PRODUCTS IN DEVELOPMENT
LX211, Luveniq™ (granted [...]
20
Oct
2009
Endocyte | Series C $26M
Posted in IN Private: Endocyte, Series A, X - Drug Delivery, X - Folate, X - Oncology, X - Therapeutic
There is some robust and diverse activity transpiring at West Lafayette, IN-based Endocyte where not one, not two but three unique business activities are transpiring concurrently. These include:
Addressing the issues of dosing and toxicity of oncologic therapeutics via a drug guidance system which is intended to improve specificity, safety and efficacy, and is payload agnostic [...]
18
Oct
2009
Integrated Diagnostics | Series A $30.1M
Posted in Series A, WA Private: Integrated Dx, X - Diagnostic
The name Leroy Hood may ring a bell to some (or most); Dr. Hood is considered among the uber-distinguished handful of architects of the molecular biotechnology revolution based upon his co-development of DNA and protein synthesis and sequencing technologies. These breakthrough contributions catalyzed the foundation of an industrial revolution, in addition Dr. Hood played a [...]
07
Oct
2009
Inviragen (Ft. Collins, CO) a preclinical-stage vaccine company focused on emerging global infectious diseases, closed a $15M Series A financing and in the process merged the assets of Singapore-based SingVax. Participants in the round include Charter Life Sciences, Venture Investors, Bio*One Capital and Phillip Private Equity. This initial round of institutional capital comes on the [...]
22
May
2008
Miragen Therapeutics, a biopharmaceutical company focused on the discovery and development of therapies for cardiovascular and muscle disease based on microRNA biology has closed an $8M Series A financing co-led by Atlas Venture and Boulder Ventures. The Miragen scientific co-founders include successful academician serial entrepreneurs Eric Olson, Ph.D., Michael Bristow, M.D., Ph.D., and Marvin Caruthers, [...]
27
Apr
2008
Evolutionary Genomics (Lafayette) an agricultural technology company who addresses the critical need to increase the availability of biofuel feedstocks has closed an undisclosed Series A financing with Denver-based Altira Group; not to be confused with the Altria Group or its much better known previous name Philip Morris (NYSE: MO).
EG’s Adapted Traits Platform is used to [...]
15
Apr
2008
Lanx: Series A $25M
Posted in CO Private: Lanx, Series A
Lanx (Broomfield) a medical device company developing and marketing surgical implants and biological products for spinal surgery closed a $25M Series A financing led by Chicago Growth Partners and also included co-investors Goldman Sachs and Oakwood Medical Investors.
The Company currently markets 15 product lines of implants and associated instrumentation for spinal fusion surgery. Lanx is [...]
06
Dec
2007
OPX Biotechnologies: Series A $3.6M
Posted in Series A
OPX Biotechnologies (Boulder) announced the close of a $3.6M Series A financing led by Mohr Davidow Ventures and X/Seed Capital Management.
OPX is enabling renewable fuels and chemicals that are economically and environmentally superior to petroleum-based products by using a pioneering technology platform known as SCALEs to enable massively parallel full genome search and modification to [...]
24
May
2007
BaroFold: Raising $12M Series A
Posted in Series A
BaroFold is raising a $12M Series A to be co-led by HBM BioVentures and Boulder Ventures and will be joined by the Peierls Foundation and other seed investors.
BaroFold has developed and patented a protein processing technology that employs hydrostatic pressure to disaggregate and refold recombinant proteins from aggregates and inclusion bodies. The PreEMT™ process refolds [...]
28
Feb
2007
CeraPedics (Lakewood, CO) developing products for the orthopedic bone substitute market announced the close of a $12.25M private equity financing from OrbiMed Advisors. The Company’s products utilize a proprietary small peptide called P-15™. This peptide has been identified to play a role in initiating the formation of bone. CeraPedics’ products may provide a [...]
01
Feb
2007
iBalance Medical (Boulder) is developing an improved method for completing an orthopedic surgical procedure called high tibial osteotomy. The company provides the surgical tools and implant for this knee malalignment corrective surgery. Back in October of 2005 I wrote about the $8.24M first tranche (here). The company has recently announced a second $5.26M tranche (also [...]
04
Dec
2006
Luca Technologies, LLC (Golden), has raised $3M from BASF Venture Capital GmbH, the corporate venture capital company of the BASF Group.
Luca develops biotechnology that uses bacteria to reactivate the production of methane (natural gas) from fuels such as coal or oil. The technology platform is based on the discovery, characterization and management of naturally [...]
03
Mar
2006
ARCA Discovery, Inc., a company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced the completion of a $15 million venture capital financing. The financing was led by Atlas Venture. Boulder Ventures, which provided the original seed financing for ARCA, and Pequot Capital Management also participated in the financing.
This round of financing [...]
Life Science Deal Flow PARTNERS
-
